Reduce uncertainty in market access

Today 90% of clinical investigations fail due to poor trial design, inability to access relevant information, difficulty in interpreting the collected data or a lack of representativity of the results. That is why a real global change of the R&D paradigm is needed to stop the decline in both the efficiency and the productivity of drug development worldwide, especially during the COVID19 pandemic.

To learn more how Novadiscovery's Modeling & Simulation can help reduce this uncertainty, download our white paper

Download our White Paper

Market_access_white_book_mockup@2x

Content of the case study

insilico@2x

Uncertainty at the time of market access 

From bench top to patients, the life of a new medical product is a continuous accrual of data aimed at answering the question: “Can the activity observed on a Petri dish result in improved health benefits for patients (and the population)?”.This data accumulation process is punctuated by decision-making taken in uncertain settings. One of the most challenging decisions because of this uncertainty is market access.

white-box-2-x@2x

The fundamentals of the NOVA Modeling & Simulation solution

The three components of NOVA’s solution are: (i) the disease model, which is a mathematical representation of the disease; (ii) the drug model, which is a mathematical representation of the behavior of the compound in the body, from administration to its target(s) in the disease model; (iii) the virtual population (VP), which is a collection of virtual individuals defined by a set of values of model parameters.

market_access@2x

A few illustrative examples for market access applications

M&S can help by eliminating most of the uncertainty that makes market access difficult.Illustration examples of Modeling & Simulation applied to market access: (i) treatment of reperfusion injury; (ii) prevention of lung graft rejection; (iii) interaction between a anti HBV NMP and established treatments; (iv) non persistent efficacy in chronic treatment.